Two years after licensing cenobamate from SK, Arvelle gets a nice payday.
The failure of OV101 puts the spotlight on Ultragenyx and Roche.
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Ovid Therapeutics gets a mid-stage win in Dravet syndrome, but might have a hard time going up against Zogenix’s Fintepla.
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
The fragile X pipeline is strewn with failures, and crunch time is approaching for Zynerba’s cannabinoid.
The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.